价格

Teva Pharma B.V.

ACTIVE

Swensweg 5, Haarlem, Noord-Holland, 荷兰www.tevapharm.comSubsidiary

别名:

teva b.v.

teva pharma

隶属于 Teva Pharmaceutical Industries Ltd.

概览

试验阶段分布

阶段

试验数

占比

3 期

38.9%

2 期

22.2%

4 期

5.6%

试验状态分布

已完成

83.3%

招募中

5.6%

撤回

11.1%

相关临床试验

该机构主办的试验（18）

Prospective Observational Study in Patients With Metastatic Breast Cancer Treated With Anthracyclines

已完成

observational

Feb 201260 名受试者

A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 versus Placebo for the Prevention of Chronic Cluster Headache

A multicenter, double-blind, randomized, active controlled, parallel-group study to evaluate the efficacy, safety, tolerability, and pharmacodynamic profiles of TL011 infusions compared with MabThera® (rituximab) in subjects with severe, active rheumatoid arthritis treated with methotrexate (MTX)

A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 versus Placebo for the Prevention of Episodic Cluster Headache

A 12-Week Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX® 160/4.5 mcg Inhalation Powder Versus SYMBICORT® TURBOHALER® 200/6 mcg in Adult and Adolescent Patients with Persistent Asthma.

A multinational, multicenter, open-label, single-assignment extension of the MS-LAQ-301 (ALLEGRO) study, to evaluate the long-term safety, tolerability and effect on disease course of daily oral laquinimod 0.6 mg in subjects with relapsing multiple sclerosis

A study to assess the safety, tolerability and pharmacokinetic properties of CEP-37248, a drug for the treatment of autoimmune inflammatory diseases, in healthy men.

已完成

interventional

93 名受试者

An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects who Participated in the ADAGIO Study

第 1 页，共 3 页

药物批准

按机构分类的批准

EMA

European Medicines Agency

药物批准

EMC

Electronic Medicines Compendium

药物批准

CIMA_AEMPS

Spanish Agency for Medicines and Medical Devices

351

药物批准

近期批准

IVACAFTOR TEVA 150 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG

CIMA_AEMPS

2026-09-01

LINAGLIPTINA TEVA 5 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG

CIMA_AEMPS

2026-07-23

GLICLAZIDA TEVAGEN 60 MG COMPRIMIDOS DE LIBERACIÓN MODIFICADA EFG

CIMA_AEMPS

2026-05-05

GLICLAZIDA TEVAGEN 30 MG COMPRIMIDOS DE LIBERACIÓN MODIFICADA EFG

CIMA_AEMPS

2026-05-05

AMLODIPINO TEVA-RATIOPHARM 5 MG COMPRIMIDOS EFG

CIMA_AEMPS

2025-12-22

APREMILAST TEVA 10 MG + 20 MG + 30 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG

CIMA_AEMPS

2025-09-18

APREMILAST TEVA 30 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG

CIMA_AEMPS

2025-09-18

TERIFLUNOMIDA TEVAGEN 14 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG

CIMA_AEMPS

2025-09-18

PAXTIBI 25 MG COMPRIMIDOS RECUBIERTOS

CIMA_AEMPS

2025-07-14

Actiq 1600 micrograms Lozenges

EMC

2025-07-07

资讯

暂无资讯文章

返回机构列表

Teva Pharma B.V.

概览

试验阶段分布

试验状态分布

相关临床试验

该机构主办的试验（18）

Prospective Observational Study in Patients With Metastatic Breast Cancer Treated With Anthracyclines

A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled,<br>Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens<br>(Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 versus Placebo for the<br>Prevention of Chronic Cluster Headache

A multicenter, double-blind, randomized, active controlled, parallel-group study to evaluate the efficacy, safety, tolerability, and pharmacodynamic profiles of TL011 infusions compared with MabThera® (rituximab) in subjects with severe, active rheumatoid arthritis treated with methotrexate (MTX)

A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled,<br>Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens<br>(Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 versus Placebo for the<br>Prevention of Episodic Cluster Headache

A 12-Week Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX® 160/4.5 mcg Inhalation Powder Versus SYMBICORT® TURBOHALER® 200/6 mcg in Adult and Adolescent Patients with Persistent Asthma.

A multinational, multicenter, open-label, single-assignment extension of the MS-LAQ-301 (ALLEGRO) study, to evaluate the long-term safety, tolerability and effect on disease course of daily oral laquinimod 0.6 mg in subjects with relapsing multiple sclerosis

A study to assess the safety, tolerability and pharmacokinetic properties of CEP-37248, a drug for the treatment of autoimmune inflammatory diseases, in healthy men.

An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects who Participated in the ADAGIO Study

药物批准

按机构分类的批准

近期批准

资讯